Global, regional and national burden of primary liver cancer by subtype-Reference-Cited by-同舟云学术

Global, regional and national burden of primary liver cancer by subtype

Published:2022-01 Issue: Volume:161 Page:108-118
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Rumgay Harriet^ORCID,Ferlay Jacques,de Martel Catherine,Georges Damien^ORCID,Ibrahim Amal Samy,Zheng Rongshou,Wei Wenqiang,Lemmens Valery E.P.P.,Soerjomataram Isabelle

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA A Cancer J Clin,2018

2. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection;Chuang;Cancer Lett,2009

3. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms;Songserm;Cancer Epidemiol,2012

4. Clinical presentation, risk factors and staging systems of cholangiocarcinoma;Plentz;Best Pract Res Clin Gastroenterol,2015

5. Surveillance Research Program. National Cancer Institute SEER∗Stat software (seer.cancer.gov/seerstat) version 8.3.8.

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

2. Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets;Journal of Clinical Medicine;2024-09-05

3. Liver and bile duct organoids and tumoroids;Biomedicine & Pharmacotherapy;2024-09

4. The Biological Clock of Liver Metabolism in Metabolic Dysfunction-Associated Steatohepatitis Progression to Hepatocellular Carcinoma;Biomedicines;2024-08-29

5. Is there added value of the hepatobiliary phase of MRI with hepatobiliary contrast agents for hepatocellular carcinoma diagnosis? A meta-analysis;Polish Journal of Radiology;2024-08-19